Strengthening 340B Program Integrity to Improve Accountability and Confidence

If 340B drug discounts represent a significant share of your revenues, you won’t want to miss this webinar.

The integrity of the 340B drug discount program is under a microscope. Covered entities must act now to demonstrate that they are good program stewards and be prepared for additional reporting requirements.

As a bipartisan group of U.S. senators reviews responses to a congressional RFI seeking input on how to improve the 340B program, Sectyr is launching an informative webinar series designed to shed light on one of the group’s most pressing questions: How to improve the accountability of the 340B program and give policymakers and industry stakeholders greater confidence in its oversight.

On October 24, join Bill von Oehsen, Principal, Powers Pyles Sutter & Verville PC, and Craig Frost, President and COO of Sectyr, as we continue our discussion on these issues and how to ensure continuous 340B program compliance.

In Part 1 of the series we discussed an update on new reporting requirements and the continuous program compliance imperative.

Topics to be addressed, in Part 2, include: 

• How the responsibility for 340B compliance has changed over time
• The shifting landscape on patient definition
• Compliance and operational implications of federal and state legislative and policy changes
• Tools available to help manage 340B compliance
• How does continuous program compliance differ from what we’re doing today?